# Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes

> **NCT00191282** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1116 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Acute Myocardial Infarction

## Interventions

- **DRUG:** Insulin lispro
- **DRUG:** Human insulin isophane suspension (NPH)
- **DRUG:** Insulin glargine
- **DRUG:** Human insulin isophane suspension
- **DRUG:** Human insulin 30/70

## Key facts

- **NCT ID:** NCT00191282
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 1116 (ACTUAL)
- **Last updated:** 2011-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191282, "Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00191282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*